PRAX News and Press, Praxis Precision Medicines Inc. From 11/03/21

Enrollment on track for 1H22 topline results for PRAX-114 Phase 2/3 monotherapy MDD Aria Study and for PRAX-114 Phase 2 dose-ranging MDD Acapella Study PRAX-114 Phase 2 studies in post-traumatic stress disorder and essential tremor (ET), PRAX-562 Phase 2 study in rare adult ceph...

BOSTON, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today ann...

Gainers: MRIN +72.9%. ALPN +22.5%. SFIX +12.8%. PRAX +5.4%. LAUR +3.3%. Losers: SMMT -19.8%. LPTX -11.4%. BDSI -8.8%. BLU -5.2%. ATAX -4.2%. For further details see: MRIN, ALPN, SMMT and LPTX among after hours movers

CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance...

Gainers: Triple-S Management (NYSE:GTS) +45%, Bio-Path (NASDAQ:BPTH) +21%, Reviva Pharmaceuticals (NASDAQ:RVPH) +21%, XTL Biopharmaceuticals (NASDAQ:XTLB) +13%, Protara Therapeutics (NASDAQ:TARA) +12%. Losers: Theravance Biopharma (NASDAQ:TBPH) ...

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks rebounded on Friday after Dallas Federal Reserve President Robert Kaplan said the surge in coronavirus cases could cause him to adjust...

Despite snapping a four-day rally on Wednesday, healthcare stocks in the S&P 500 gained for two consecutive sessions to end the week ~1.8% higher, outperforming the ~0.6% loss in the broader index. Among healthcare stocks with more than $300M market cap and over 100K averag...

Initiated PRAX-114 Phase 2 Acapella Study for adjunctive treatment of Major Depressive Disorder (MDD) Enrollment on track for 1H22 topline results in PRAX-114 Phase 2/3 Aria Study for monotherapy treatment of MDD PRAX-114 to advance in Phase 2b study in women with menopa...

PRAX-114 showed rapid and marked improvements in menopausal and mood symptoms in Phase 2a PMD study PRAX-114 was well tolerated in Phase 2a PMD study with no change in overall safety profile CAMBRIDGE, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines ...

CAMBRIDGE, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance,...